ANI Pharmaceuticals
(NASDAQ:ANIP)
$63.77
0[0.00%]
At close: May 16
$63.77
0[0.00%]
PreMarket: 4:03PM EDT
Q1 2024 Earnings were released on Fri May 10th, before the market open
The most recent conference call was at 8:30 AM, 7 days ago Click to view past webcast
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest
62.5%
Overview Rating
Good
Technicals Analysis
100
0100
Financials Analysis
40
0100

ANI Pharmaceuticals Stock (NASDAQ:ANIP), Quotes and News Summary

ANI Pharmaceuticals Stock (NASDAQ: ANIP) stock price, news, charts, stock research, profile.

Open-
Close-
Volume / Avg.0 / 158.862K
Day Range- - -
52 Wk Range40.550 - 70.810
Market Cap$1.337B
P/E Ratio39.609
Dividend Yield-
ExchangeNASDAQ
RSI
38
Short Interest
1.42%
Days to Cover2.1

Recent News

Merck Ends Keytruda Combo Melanoma Study Due to Futility
Merck (NYSE: MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor, Keytruda plus vibostolimab, its investigational anti-TIGIT antibody, as adjuvant treatment for patients with resected high-risk melanoma.
Zacks
Perrigo Q1 Earnings Surpass, Sales Miss Estimates
Perrigo Company plc (NYSE: PRGO) reported adjusted earnings of 29 cents per share in the first quarter of 2024, beating the Zacks Consensus Estimate of 24 cents. Earnings were down 35.6% year over year, primarily due to a negative financial impact of 30 cents per share from infant formula.
Zacks
Puma Biotechnology's Q1 Earnings and Revenues Beat
Puma Biotechnology, Inc. (NASDAQ: PBYI) reported first-quarter 2024 adjusted loss of 5 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 16 cents. In the year-ago quarter, the company had reported adjusted earnings of 9 cents.
Zacks
40%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
1
Feb
4
Mar
1
Apr
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Compare

EPS better than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
ANIP
SUPN

FAQ

Q

How do I buy ANI Pharmaceuticals (ANIP) stock?

A

You can purchase shares of ANI Pharmaceuticals (NASDAQ: ANIP) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are ANI Pharmaceuticals's (ANIP) competitors?

A

Other companies in ANI Pharmaceuticals’s space includes: Supernus Pharmaceuticals (NASDAQ:SUPN), Verona Pharma (NASDAQ:VRNA), Tarsus Pharmaceuticals (NASDAQ:TARS), Phibro Animal Health (NASDAQ:PAHC) and Neumora Therapeutics (NASDAQ:NMRA).

Q

What is the target price for ANI Pharmaceuticals (ANIP) stock?

A

The latest price target for ANI Pharmaceuticals (NASDAQ: ANIP) was reported by HC Wainwright & Co. on Monday, May 13, 2024. The analyst firm set a price target for 87.00 expecting ANIP to rise to within 12 months (a possible 36.43% upside). 14 analyst firms have reported ratings in the last year.

Q

Current Stock Price for ANI Pharmaceuticals (ANIP)?

A

The stock price for ANI Pharmaceuticals (NASDAQ: ANIP) is $63.77 last updated May 16, 2024 at 4:03 PM EDT.

Q

Does ANI Pharmaceuticals (ANIP) pay a dividend?

A

There are no upcoming dividends for ANI Pharmaceuticals.

Q

When is ANI Pharmaceuticals (NASDAQ:ANIP) reporting earnings?

A

ANI Pharmaceuticals’s Q2 earnings are confirmed for Wednesday, August 7, 2024.

Q

Is ANI Pharmaceuticals (ANIP) going to split?

A

There is no upcoming split for ANI Pharmaceuticals.

Q

What sector and industry does ANI Pharmaceuticals (ANIP) operate in?

A

ANI Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch